New drug aims to soften skin and protect lungs in rare disease
NCT ID NCT07047690
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called nemolizumab in 162 adults with systemic sclerosis, a disease that causes skin thickening and can harm internal organs. Participants receive either nemolizumab or a placebo as a shot under the skin for 52 weeks. The main goal is to see if the drug reduces skin hardness and to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nemolizumab (a drug given as a shot under the skin)
What this could lead to
If it works, this could point toward a new treatment to control skin hardening and possibly slow lung damage in systemic sclerosis.
What could go wrong
This is an early Phase 2 trial with only 162 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Galderma Investigational Site # 6213
RECRUITINGSankt Gallen, 9007, Switzerland
Contact
-
Galderma Investigational Site # 8743
RECRUITINGAnn Arbor, Michigan, 48109-5000, United States
Contact
-
Galderma Investigational Site#7096
RECRUITINGArlington, Texas, 76012, United States
Contact